• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6/18/25 2:09:19 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care
    Get the next $SVA alert in real time by email
    6-K 1 tm2518308d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2025

     

     

    Commission File Number: 001-32371

     

     

    SINOVAC BIOTECH LTD.

     

    No. 39 Shangdi Xi Rd, Haidian District

    Beijing 100085, People’s Republic of China

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F    x          Form 40-F    ¨

     

     

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      SINOVAC BIOTECH LTD.
         
      By: /s/ Chiang Li
      Name: Dr. Chiang Li
      Title: Chairman of the Board of Directors

     

    Date: June 18, 2025

     

     

     

     

    Exhibit Index

     

    Exhibit 99.1   Notice and Proxy Statement for the Company’s Special Meeting of Shareholders to be held on July 8, 2025
         
    Exhibit 99.2   Form of Proxy Card for the Company’s Special Meeting of Shareholders to be held by July 8, 2025

     

     

     

     

    Get the next $SVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SVA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SVA
    SEC Filings

    View All

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    7/10/25 9:54:16 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    7/9/25 9:53:38 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    7/9/25 9:55:18 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

    Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court's interlocutory order governing the Company's board composition and corporate actions pending trial, and announced the engagement of Zhonghua Certified Public Accountants LLP ("Zhonghua"), an affiliate of the global accounting network UHY International, as the Company's independent auditor and registered public accounting firm. Update on Antigua High Court Order Further to the order issued by the Antigua High Court (the "Court") previously disclosed by the Company in a press release dated December 17, 2025, the Cour

    1/4/26 10:13:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

    Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the "Notification Letter") from Nasdaq Listing Qualifications ("Nasdaq"), stating that the Company was not in compliance with Nasdaq's Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025. As previously disclosed, the Company received a delisting determination letter (the "Staff Determination") from Nasdaq in November 2025. The Company requested a hearing before t

    1/4/26 10:00:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting

    Sinovac Biotech Ltd. (NASDAQ:SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the Board), will comprise the Board of the Company until the trial listed in late April/early May 2026. The Antigua High Court decision arises from a hearing that took place on 27 October 2025, at which applicants SAIF Partners IV L.P., OrbiMed Partners Master Fund Limited and 1Globe Capital LLC each sought injunctions to confirm the composition of their r

    12/17/25 7:00:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Leadership Updates

    Live Leadership Updates

    View All

    SINOVAC Announces Appointment of Independent Auditor

    Critical step in improving transparency and resuming trading on NASDAQ The Board of Directors and Management of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Audit Committee of the Board has approved the engagement of UHY LLP ("UHY") headquartered in the U.S. as its independent auditor and registered public accounting firm, effective today, October 24, 2025. UHY is a U.S. member of Urbach Hacker Young International Limited (UHY International), a UK company, and forms part of the international UHY network of legally independent accounting and consulting firms. As a matter of priority, UH

    10/24/25 10:30:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders

    Special Meeting validly adjourned until the appropriate court makes a final decision on validity of the PIPE shares and will be reconvened SAIF and the Dissenting Investor Group's deceptive claims of a "continuation of the Special Meeting" and a pretend "Board" are fake and without legal basis Current Board remains the only valid board of directors of SINOVAC and will continue to govern the Company The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company") today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the "Special Meeting"): The Special Meeting was validly adjourned by SINOVAC Chairman Chian

    7/11/25 4:21:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC

    Court denies Vivo Capital's petition for relief relating to shareholder votes and corporate governance, clearing another legal hurdle for distribution of the US$55.00 per common share special cash dividend Marks fourth unsuccessful legal attempt in deceptive and disparaging campaign by Advantech/Prime or Vivo Capital against current Board and its Chairman New reports from two leading independent proxy advisory firms, Glass Lewis and ISS, firmly recommend shareholders vote to KEEP the current Board chaired by Dr. Chiang Li The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced

    7/7/25 1:46:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Financials

    Live finance-specific insights

    View All

    /C O R R E C T I O N -- Heng Ren Partners/

    In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issued Nov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared b

    11/11/25 5:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Newly Elected Directors of Sinovac Hold the First Board Meeting

    Mr. Andrew Y. Yan elected Chairman of the Board New Board Unanimously Resolved to Explore Future Dividend Plans, Conduct Search for New Auditor for Resuming NASDAQ Trading, and Restore Stable Operations of the Company, Amongst Other Things Sinovac Biotech Ltd. (NASDAQ:SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the new Directors), held its first meeting today at the Company's headquar

    7/10/25 7:23:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment

    Special cash dividend is being paid to valid common shareholders who owned SINOVAC as of the close of business on July 7, 2025 Board will continue to prioritize dividend distributions according to its previously announced policy For any questions about the dividend payment process, shareholders should contact Dividend Information Agent D.F. King at [email protected] The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the previously declared US$55.00 per common share special cash dividend is in the process of being paid to valid shareholders who owned SINOVAC shares as of

    7/9/25 12:27:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

    SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    9/12/24 4:03:46 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

    SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    6/17/24 4:02:44 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Sinovac Biotech, Ltd. (Amendment)

    SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    3/20/24 7:33:23 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care